Latest News
Conference Coverage
GSI may boost BCMA CAR T-cell therapy efficacy in myeloma
Gamma secretase inhibition may lead to improved outcomes in multiple myeloma patients treated with BCMA-specific CAR T-cell therapy.
From the Journals
Does incretin therapy increase pancreatic cancer risk?
It is unlikely the drugs actually caused the increase in cancer risk.
News from the FDA/CDC
FDA grants orphan drug status to rofecoxib for hemophilic arthropathy
An nonopioid treatment for hemophilic arthropathy could be on the way.
Conference Coverage
CAR T-cells gain ground against hematologic cancers
New data from the ZUMA-1 and JULIET studies will be presented at ASH 2017.
Conference Coverage
Late-breaking abstracts highlight treatment advances in CLL, myeloma, and more
ASH President Kenneth C. Anderson, MD, and ASH Secretary Robert A. Brodsky, MD, gave a preview of four practice-changing studies.
Latest News
CMS to enlist Medicare Part D plans to combat opioid abuse
Officials would like to extend the use the criteria for overutilizers to identify at-risk beneficiaries, then allow insurers to limit their access...
Conference Coverage
CD22 CAR activity in B-ALL highlights promise of multispecific CARs
NATIONAL HARBOR, MD. – A new CD22-targeted CAR demonstrated clinical activity in relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL)...
From the Journals
Mayo experts outline Waldenström macroglobulinemia management
The guidelines are based on studies and expert consensus.
Feature
CAR T-cell therapy: Moving from cost to value
Cost and value issues temper CAR T-cell therapy enthusiasm.
Conference Coverage
Emerging sickle cell agents target new pathways
CONCORD, N.C. – There are a number of new drugs in the sickle cell disease pipeline, and researchers are investigating gene therapy using patients...
Conference Coverage
Dedicated sickle cell center offers roadmap for care
CONCORD, N.C. – The Georgia Comprehensive Sickle Cell Center includes a dedicated emergency room.